echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Phase 1/2 clinical trial of nitric oxide synthase inhibitor L-NMMA and taxane in the treatment of chemotherapy-resistant triple-negative breast cancer

    Phase 1/2 clinical trial of nitric oxide synthase inhibitor L-NMMA and taxane in the treatment of chemotherapy-resistant triple-negative breast cancer

    • Last Update: 2021-12-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Successful combination

    A phase 1/2 clinical trial tested the effects of inducible nitric oxide synthase inhibitor (L-NMMA) combined with taxane in the treatment of refractory locally advanced breast cancer (LABC) and metastatic triple-negative breast cancer (TNBC) Curative effect


    The total effective rate was 45.


    Previous studies using in vivo models have shown that the use of pan-NOS inhibitor NG-methyl can inhibit the iNOS signaling pathway-I-Arginine (L-NMMA) reduces tumor growth and improves survival in TNBC patients


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.